Last reviewed · How we verify
Recombinant Anti-EGFr Antibody — Competitive Intelligence Brief
phase 1
Biologic
Live · refreshed every 30 min
Target snapshot
Recombinant Anti-EGFr Antibody (Recombinant Anti-EGFr Antibody) — Sichuan Kelun Pharmaceutical Co., Ltd.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Recombinant Anti-EGFr Antibody TARGET | Recombinant Anti-EGFr Antibody | Sichuan Kelun Pharmaceutical Co., Ltd | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Recombinant Anti-EGFr Antibody CI watch — RSS
- Recombinant Anti-EGFr Antibody CI watch — Atom
- Recombinant Anti-EGFr Antibody CI watch — JSON
- Recombinant Anti-EGFr Antibody alone — RSS
Cite this brief
Drug Landscape (2026). Recombinant Anti-EGFr Antibody — Competitive Intelligence Brief. https://druglandscape.com/ci/recombinant-anti-egfr-antibody. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab